Title | Gut Microbial-Derived Metabolites as Immune Modulators of T Helper 17 and Regulatory T Cells. |
Publication Type | Journal Article |
Year of Publication | 2023 |
Authors | Calvo-Barreiro L, Zhang L, Abdel-Rahman SA, Naik SParitosh, Gabr M |
Journal | Int J Mol Sci |
Volume | 24 |
Issue | 2 |
Date Published | 2023 Jan 16 |
ISSN | 1422-0067 |
Keywords | Gastrointestinal Microbiome, Humans, Immune System, Microbiota, T-Lymphocytes, Regulatory |
Abstract | The gut microbiota and its derived metabolites greatly impact the host immune system, both innate and adaptive responses. Gut dysbiosis and altered levels of microbiota-derived metabolites have been described in several immune-related and immune-mediated diseases such as intestinal bowel disease, multiple sclerosis, or colorectal cancer. Gut microbial-derived metabolites are synthesized from dietary compounds ingested by the host or host-produced metabolites, and additionally, some bacterial products can be synthesized de novo. In this review, we focus on the two first metabolites families including short-chain fatty acids, indole metabolites, polyamines, choline-derived compounds, and secondary bile acids. They all have been described as immunoregulatory molecules that specifically affect the adaptive immune system and T helper 17 and regulatory T cells. We discuss the mechanisms of action and the consequences in health and diseases related to these gut microbial-derived metabolites. Finally, we propose that the exogenous administration of these molecules or other compounds that bind to their immunoregulatory receptors in a homologous manner could be considered therapeutic approaches. |
DOI | 10.3390/ijms24021806 |
Alternate Journal | Int J Mol Sci |
PubMed ID | 36675320 |
PubMed Central ID | PMC9867388 |
Related Institute:
Molecular Imaging Innovations Institute (MI3)